U.S. Osteoarthritis Injectables Market
U.S. Osteoarthritis Injectables Market Analysis 2024-2030: Rising Prevalence of Osteoarthritis & Increase in R&D Activities for Injectable Drug Developments Spurs Growth
October 04, 2024 05:52 ET | Research and Markets
Dublin, Oct. 04, 2024 (GLOBE NEWSWIRE) -- The "U.S. Osteoarthritis Injectables Market Size, Share & Trends Analysis Report by Injection Type (Hyaluronic Acid Injections, Corticosteroids...
ENLIVEX centric logo_white.jpg
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
September 26, 2024 08:30 ET | Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Picture1.jpg
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
September 24, 2024 08:30 ET | Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Picture1
PetVivo Taps Top Sales Executive, Skylor Walker, for Regional Business Development Manager, as Adoption of Breakthrough Animal MedTech Device Continues to Spread Nationwide
September 16, 2024 08:00 ET | PetVivo Holdings, Inc.
MINNEAPOLIS, MN, Sept. 16, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Skylor...
Logo.png
PetVivo’s Spryng with OsteoCushion™ Technology Featured in Visionaries on Bloomberg TV
September 12, 2024 08:00 ET | PetVivo Holdings, Inc.
MINNEAPOLIS, MN, Sept. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics for equines and companion animals, was recently...
Logo.png
PetVivo Teams with Orthobiologic Innovations for Clincial Research and Product Commercialization
August 27, 2024 08:00 ET | PetVivo Holdings, Inc.
Orthobiologic President & CEO, Sherman O. Canapp, Jr. and Director of Diagnositcs and Education, Debra Cannap, Join PetVivo Advisory Board MINNEAPOLIS, MN, & Annapolis Junction, MD, US,...
Logo.png
Anthony Germinaro Joins PetVivo Holdings, Inc. as a Field Veterinary Business Development Manager
August 19, 2024 10:10 ET | PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Aug. 19, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of...
Logo.png
PetVivo Reports Reports Fiscal Q1 2025 Results
August 14, 2024 16:25 ET | PetVivo Holdings, Inc.
Company Reieterates Gudience of 50% to 100% Revenue Growth in Fiscal 2025 MINNEAPOLIS, MN, US, Aug. 14, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical...
Crescent Innovations reports strong interest in asset sale
August 13, 2024 08:30 ET | Crescent Innovations Inc.
Crescent Innovations Inc. reports that activity surrounding sale of its joint, bone and skin repair technology remains strong even at this late date.
1
Eric Samples Joins PetVivo Holdings, Inc. as a Field Veterinary Business Development Manager
August 12, 2024 13:52 ET | PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Aug. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of...